Liver study tests drug processing in impaired patients
NCT ID NCT06052566
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looked at how the drug efinopegdutide behaves in people with moderate to severe liver damage compared to healthy people. A total of 22 adults took a single dose, and researchers measured drug levels and safety. The goal was to understand dosing needs for patients with liver problems, not to treat the disease.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATIC IMPAIRMENT are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Advanced Pharma CR, LLC ( Site 0001)
Miami, Florida, 33147, United States
-
American Research Corporation ( Site 0002)
San Antonio, Texas, 78215, United States
-
Clinical Pharmacology of Miami ( Site 0005)
Miami, Florida, 33014-3616, United States
-
Genesis Clinical Research, LLC ( Site 0006)
Tampa, Florida, 33603, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Liver health and drug processing: a closer look at casdatifan
- A new MRI technique could see inside the Liver's metabolism without a biopsy
- Blood test and AI could spot liver cancer early, saving lives
- Liver function may change how belapectin works in the body
- Liver function may change how ammoxetine works
- Liver function may affect how Weight-Loss drug petrelintide works